Subcutaneous semaglutide vs. placebo as adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity

What The Study Did:
This randomized clinical trial compares the effects of once-weekly subcutaneous semaglutide versussplacebo for weight management as an adjunct to intensive behavioral therapy with initial low-calorie diet in adults with overweight or obesity.

Authors: 
Thomas A. Wadden, Ph.D., of the University of Pennsylvania in Philadelphia, is the corresponding author.

To access the embargoed study:
Visit our For The Media website at this link
https://media.jamanetwork.com/

(doi:10.1001/jama.2021.1831)

Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

INFORMATION:

Media advisory:
The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article 
This link will be live at the embargo time
https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2021.1831?guestAccessKey=5d38b335-f31a-4bd8-8fbf-167360ac109d&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=022421